Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis

2016 ◽  
Vol 148 ◽  
pp. 79-84 ◽  
Author(s):  
Zhi-Feng Wang ◽  
Hong-Lin Chen
Keyword(s):  
Meta Analysis ◽  
Idh1 Mutation ◽  
Low Grade ◽  
Low Grade Gliomas

scholarly journals Management of low-grade glioma: a systematic review and meta-analysis

2018 ◽  
Vol 6 (4) ◽  
pp. 249-258 ◽  
Author(s):  
Timothy J Brown ◽  
Daniela A Bota ◽  
Martin J van Den Bent ◽  
Paul D Brown ◽  
Elizabeth Maher ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Low Grade Glioma ◽  
World Health ◽  
Subtotal Resection ◽  
Low Grade ◽  
Evidence Based ◽  
Free Survival ◽  
Low Grade Gliomas

Abstract Background Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma. Methods A quantitative systematic review was performed. Inclusion criteria included controlled trials of newly diagnosed low-grade (World Health Organization Grades I and II) gliomas in adults. Eligible studies were identified, assigned a level of evidence for every endpoint considered, and analyzed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The relative risk of mortality and of progression at 2, 5, and 10 years was calculated for patients undergoing resection (gross total, subtotal, or biopsy), radiation, or chemotherapy. Results Gross total resection was significantly associated with decreased mortality and likelihood of progression at all time points compared to subtotal resection. Early radiation was not associated with decreased mortality; however, progression-free survival was better at 5 years compared to patients receiving delayed or no radiation. Chemotherapy was associated with decreased mortality at 5 and 10 years in the high-quality literature. Progression-free survival was better at 5 and 10 years compared to patients who did not receive chemotherapy. In patients with isocitrate dehydrogenase 1 gene (IDH1) R132H mutations receiving chemotherapy, progression-free survival was better at 2 and 5 years than in patients with IDH1 wild-type gliomas. Conclusions Results from this review, the first to quantify differences in outcome associated with surgery, radiation, and chemotherapy in patients with low-grade gliomas, can be used to inform evidence-based management and future clinical trials.

scholarly journals IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis

Seizure ◽  
2018 ◽  
Vol 55 ◽  
pp. 76-82 ◽  
Author(s):  
Yucai Li ◽  
Xia Shan ◽  
Zhifeng Wu ◽  
Yinyan Wang ◽  
Miao Ling ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Idh1 Mutation ◽  
Low Grade Glioma ◽  
Low Grade

Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features

2018 ◽  
Vol 49 (3) ◽  
pp. 808-817 ◽  
Author(s):  
Yan Ren ◽  
Xi Zhang ◽  
Wenting Rui ◽  
Haopeng Pang ◽  
Tianming Qiu ◽  
...  
Keyword(s):  
Idh1 Mutation ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Expression Loss

scholarly journals A Visually Interpretable, Dictionary-Based Approach to Imaging-Genomic Modeling, With Low-Grade Glioma as a Case Study

2018 ◽  
Vol 17 ◽  
pp. 117693511880279 ◽  
Author(s):  
Srikanth Kuthuru ◽  
William Deaderick ◽  
Harrison Bai ◽  
Chang Su ◽  
Tiep Vu ◽  
...  
Keyword(s):  
Dictionary Learning ◽  
Clinical Decision Making ◽  
Genetic Alterations ◽  
Idh1 Mutation ◽  
Response To Therapy ◽  
Diagnostic Process ◽  
Low Grade ◽  
Imaging Features ◽  
Data Set ◽  
Low Grade Gliomas

Radiomics is a rapidly growing field in which sophisticated imaging features are extracted from radiology images to predict clinical outcomes/responses, genetic alterations, and other outcomes relevant to a patient’s prognosis or response to therapy. This approach can effectively capture intratumor phenotypic heterogeneity by interrogating the “larger” image field, which is not possible with traditional biopsy procedures that interrogate specific subregions alone. Most models in radiomics derive numerous imaging features (eg, texture, shape, size) from a radiology data set and then learn complex nonlinear hypotheses to solve a given prediction task. This presents the challenge of visual interpretability of radiomic features necessary for effective adoption of radiomic models into the clinical decision-making process. To this end, we employed a dictionary learning approach to derive visually interpretable imaging features relevant to genetic alterations in low-grade gliomas. This model can identify regions of a medical image that potentially influence the prediction process. Using a publicly available data set of magnetic resonance imaging images from patients diagnosed with low-grade gliomas, we demonstrated that the dictionary-based model performs well in predicting 2 biomarkers of interest (1p/19q codeletion and IDH1 mutation). Furthermore, the visual regions (atoms) associated with these dictionaries show association with key molecular pathways implicated in gliomagenesis. Our results show that dictionary learning is a promising approach to obtain insights into the diagnostic process and to potentially aid radiologists in selecting physiologically relevant biopsy locations.

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

2013 ◽  
Vol 113 (2) ◽  
pp. 277-284 ◽  
Author(s):  
Hairui Sun ◽  
Lianhu Yin ◽  
Showwei Li ◽  
Song Han ◽  
Guangrong Song ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Prognostic Significance ◽  
Low Grade ◽  
Idh Mutation ◽  
Low Grade Gliomas

Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: a systematic review and meta-analysis

2019 ◽  
Vol 61 (5) ◽  
pp. 525-534 ◽  
Author(s):  
Chong Hyun Suh ◽  
Ji Eun Park ◽  
Seung Chai Jung ◽  
Choong Gon Choi ◽  
Sang Joon Kim ◽  
...  
Keyword(s):  
Systematic Review ◽  
Proton Transfer ◽  
Meta Analysis ◽  
Amide Proton ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Amide Proton Transfer

scholarly journals The Prevalence of BRAF Mutations in Patients with Glioma: A Systematic Review

2019 ◽  
Vol 21 (Supplement_4) ◽  
pp. iv13-iv13
Author(s):  
Saanwalshah Samir Saincher ◽  
Julian P T Higgins ◽  
Alexandra McAleenan ◽  
Kathreena M Kurian
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Age Groups ◽  
Low Grade ◽  
Braf Inhibitors ◽  
Braf Mutations ◽  
Low Grade Gliomas ◽  
Promising Area ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Abstract Background The V600mutation in the v-raf murine sarcoma oncogene homologue B1 (BRAF) enzyme, is a potential clinically actionable target in gliomas. BRAF inhibitors are in wide clinical use for other tumour types, particularly melanoma. The prevalence of this mutation across all gliomas is not fully elucidated and is needed to inform potential screening and treatment. Methods A systematic review using articles on the MEDLINE and EMBASE databases (February 1, 2019) was carried out. A meta-analysis was conducted to calculate the prevalence of BRAF mutations in patients with gliomas across all populations and age groups in a clinical setting. Preliminary Results The review identified 75 studies including 6316 patients; the ages of participants ranged from 30 days to 90 years with a mean age of 32.75 years. Across all studies, the average prevalence of BRAF mutations was 16% (95% confidence interval (CI) from 12% to 20%) but estimates were highly variable across studies, ranging from 0% to 78%. The average prevalence of BRAF mutations in paediatric group was 15% (95% CI 10% to 20%) while the average prevalence in the adult group was 9% (95% CI 4% to 16%). Low grade gliomas had an average prevalence of 19% (95% CI 14% to 25%) compared with 7% (95% CI 4% to 11%) in high-grade gliomas. Conclusions BRAF mutations were found to be more prevalent in pediatric patients and in low grade gliomas. Screening these patients for BRAF mutations and treating them with BRAF inhibitors represents a promising area of future medical practice.

Sign in / Sign up

Export Citation Format

Share Document